Natalizumab discontinuation in a Dutch real-world cohort.
Multiple sclerosis
Natalizumab
Treatment discontinuation
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
21
01
2021
revised:
12
04
2021
accepted:
18
04
2021
pubmed:
15
5
2021
medline:
7
7
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort. Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC. Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity. JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.
Identifiants
pubmed: 33990055
pii: S2211-0348(21)00241-8
doi: 10.1016/j.msard.2021.102974
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Natalizumab
0
Types de publication
Letter
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102974Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.